Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN DIEGO, CA, May 8, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. “In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% re ...

The earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies, Viatris (VTRS) and Perrigo Company (PRGO) , and some other drug/generic companies due to report their first-quarter 2024 results this week.The majority of the large drugmakers have already reported their results. Many of these companies beat estimates for both earnings and sales. Some companies also raised their guidance for 2024, mainly the earnings per share outlook.Per the Zacks classification, the pharma ...

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition.Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many promising growth ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is ...

Key TakeawaysAcadia Pharmaceuticals' drug missed endpoints for treating schizophrenia patients, news that sent Acadia shares sharply lower.The drug maker was looking at the potential use of its current Parkinson's psychosis medicine, Nuplazid.Acadia said it would not hold any more clinical trials for Nuplazid.Shares in Acadia were down more than 16% in late-afternoon trading. Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expa ...

Acadia Pharmaceuticals Inc. (ACAD) shares lost 15% in the after-market hours on Mar 11, after the company announced the failure of its late-stage study evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.In the phase III ADVANCE-2 study, treatment with pimavanserin did not achieve statistical significance in demonstrating improvement over placebo on the study’s primary endpoint of change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score. The NSA- ...

Acadia Pharmaceuticals (NASDAQ:ACAD) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin.Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia. Unfortunately, the Phase 3 clinical trial of pimavanserin failed to meet its primary endpoint.Acadia Pharmaceuticals CEO Steve Davis said the following in about the clinical trial results.“We are disappointed the trial did not meet its primary end ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profi ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing br ...

Acadia Pharmaceuticals Inc. (ACAD) reported fourth-quarter 2023 earnings of 28 cents per share, missing the Zacks Consensus Estimate of 32 cents. In the year-ago quarter, the company had incurred a loss of 26 cents per share.The bottom line improved year over year owing to higher product sales.The company recorded total revenues of $231 million in the fourth quarter, surpassing the Zacks Consensus Estimate of $223 million. Acadia’s net product revenues comprise revenues generated from the sale of its two ma ...